Changes to Prospective Drug Utilization Review Alerts

This *ForwardHealth Update* describes changes for prospective Drug Utilization Review (DUR) alerts that have been generated as a result of analysis and recommendations made to the DUR Board by the Department of Health Services’ pharmacy team.

**Pregnancy Alert**

Effective for dates of process on and after May 15, 2012, the list of diagnosis codes that identify pregnancy or termination of pregnancy has been updated to ensure that the most current and most specific diagnosis codes are being used for the pregnancy prospective DUR alert.

**Drug-Drug Interaction**

Effective for dates of process on and after July 1, 2012, providers will no longer receive the drug-drug interaction prospective DUR alert when the pharmacy and prescriber from a current claim matches the pharmacy and prescriber from a claim in ForwardHealth history.

**Therapeutic Duplication**

Effective for dates of process on and after July 1, 2012, providers will no longer receive the therapeutic duplication prospective DUR alert when the pharmacy and prescriber from a current claim matches the pharmacy and prescriber from a claim in ForwardHealth history.

Also, effective for dates of process on and after July 1, 2012, providers will receive the therapeutic duplication prospective DUR alert when another drug that is present in claims history is in the same therapeutic class as the drug being dispensed. Previously, the therapeutic duplication prospective DUR alert monitored drugs for the same active ingredient. Refer to the Attachment of this *Update* for a list of these codes.
of therapeutic duplication drug classes for the therapeutic
duplication prospective DUR alert.

**Suboptimal Regimen**

Effective for dates of process on and after March 20, 2012,
the suboptimal regimen prospective DUR alert has been
discontinued, although providers are encouraged to continue
to split tablets or consolidate doses when clinically
appropriate and cost-effective.

**Patient Age**

Effective for dates of process on and after July 6, 2012, the
patient age prospective DUR alert has been discontinued.
This includes both the geriatric (members who are 65 years
of age and older) and the pediatric (members who are 18
years of age and younger) components of the alert.

**Information Regarding Managed Care
Organizations**

This *Update* contains fee-for-service policy for members
enrolled in Medicaid and BadgerCare Plus who receive
pharmacy services on a fee-for-service basis only. Pharmacy
services for Medicaid members enrolled in the Program of
All-Inclusive Care for the Elderly (PACE) and the Family
Care Partnership are provided by the member’s managed
care organization.

The *ForwardHealth Update* is the first source of program
policy and billing information for providers.

Wisconsin Medicaid, BadgerCare Plus, SeniorCare, and
Wisconsin Chronic Disease Program are administered by
the Division of Health Care Access and Accountability,
Wisconsin Department of Health Services (DHS). The
Wisconsin Well Woman Program is administered by the
Division of Public Health, Wisconsin DHS.

For questions, call Provider Services at (800) 947-9627
or visit our Web site at [www.forwardhealth.wi.gov/](http://www.forwardhealth.wi.gov/).
ATTACHMENT

Therapeutic Duplication Drug Classes

The therapeutic duplication drug classes for the therapeutic duplication prospective drug utilization review alert include the following:

- Anti-anxiety agents.
- Antidepressants.
- Antihistamines.
- Antihypertensives.
- Antipsychotics.
- Antithrombotics.
- Barbiturates.
- Cardiovascular agents.
- Diuretics.
- Histamine H2 receptor inhibitors.
- Hypoglycemics.
- Narcotic analgesics.
- Nonsteroidal Anti-Inflammatory Drugs (including COX2 selective agents).
- Oral contraceptives.
- Platelet aggregation inhibitors.
- Proton pump inhibitors.
- Sedative-hypnotics.
- Skeletal muscle relaxants.